financetom
Business
financetom
/
Business
/
YES Bank softens stance; likely to approve Coffee Day-Blackstone deal, says report
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
YES Bank softens stance; likely to approve Coffee Day-Blackstone deal, says report
Dec 16, 2019 1:21 AM

In a major relief to Coffee Day Enterprises (CDEL), the group's largest creditor YES Bank is expected to give approval for proposed sale of Global Village Technology Park to private equity firm Blackstone Group, according to a Business Standard report. Earlier, the private sector lender had expressed its reservation in giving approval to the Rs 2,800-crore deal.

Share Market Live

NSE

According to the report, YES Bank has softened its stance and decided to render the ‘no objection’ to the Bengaluru-based firm’s decision to the deal. A formal letter of approval is expected to reach Coffee Day Group in the next two-three days, the report said citing sources.

The Group is trying to sell its 90-acre tech park on the outskirts of Bengaluru for repaying debts of Cafe Coffee Day’s (CCD) associate firms and their promoters after its founder V.G. Siddhartha committed suicide in July.

YES Bank is the single-largest lender to the group and its promoters. It has an exposure of at least Rs 1,500 crore to Coffee Day Group firms and their promoters. The company has about $1 billion debt burden on it.

Earlier, YES Bank had reportedly put a condition that it will give its “no objection" to the deal only if Coffee Day agrees to repay the entire loan taken by the group from the bank.

YES Bank, which is dealing with its own liquidity crunch, is the only creditor which has not yet approved the deal with the private equity giant.

First Published:Dec 16, 2019 10:21 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novartis taps Arvinas' cancer drug for up to $1 billion
Novartis taps Arvinas' cancer drug for up to $1 billion
Apr 11, 2024
April 11 (Reuters) - Swiss drugmaker Novartis AG has entered into a licensing deal worth up to $1.01 billion with Arvinas ( ARVN ) to gain access to the U.S. biotech firm's experimental prostate cancer drug, Arvinas ( ARVN ) said on Thursday. Shares of Connecticut-based Arvinas ( ARVN ) rose more than 6% to $39 in premarket trade. The...
Activist Bluebell proposes Google executive as Telecom Italia CEO
Activist Bluebell proposes Google executive as Telecom Italia CEO
Apr 11, 2024
MILAN, April 11 (Reuters) - Activist investor Bluebell Capital Partners is proposing to nominate an outgoing Google executive as candidate for the role of CEO of Telecom Italia (TIM), in a challenge to Pietro Labriola's bid for a second term. In a document presenting Bluebell's vision for TIM, seen by Reuters, it proposed Laurence Lafont, the outgoing vice-president for strategic...
Market Chatter: Spotify Technology Developing Editing Tools for Users
Market Chatter: Spotify Technology Developing Editing Tools for Users
Apr 11, 2024
08:58 AM EDT, 04/11/2024 (MT Newswires) -- Spotify Technology ( SPOT ) is developing tools that would allow subscribers to edit songs from their favorite artists, The Wall Street Journal reported Thursday, citing people familiar with the discussions. The new tools the audio-streaming company is considering include a playback feature that would allow users to adjust the speed of a...
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
Apr 11, 2024
On Wednesday, Vertex Pharmaceuticals Incorporated ( VRTX ) agreed to acquire Alpine Immune Sciences Inc ( ALPN ) for $65 per share or approximately $4.9 billion in cash.  Alpine’s lead molecule, povetacicept (ALPN-303), is a highly potent and effective dual antagonist of BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand).  Through Phase 2 development, povetacicept has shown potential best-in-class efficacy in IgA...
Copyright 2023-2026 - www.financetom.com All Rights Reserved